SCHEMBL21411380

SCHEMBL21411380

COC(=O)c1sc(CNC(=O)OC(C)(C)C)cc1NC(C)=O

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
MAPT P10636 1/20 0.46
RAF1 P04049 12/20 0.41
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
PPARG P37231 1/20 0.39
NCOA2 Q15596 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPK14 Q16539 7/20 0.38
MAPK13 O15264 1/20 0.38
MAPK12 P53778 1/20 0.38
MAPK11 Q15759 1/20 0.38
KDM4A O75164 1/20 0.37
DYRK1A Q13627 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21411397 0.89 HDAC1 (0.38) KDM4EALDH1A1LMNAMAPTGAA
SCHEMBL4169623 0.80 RAF1 (0.44) KDM4ERAF1MAPK14MAPK13MAPK12
SCHEMBL4769749 0.78 RAF1 (0.43) KDM4ERAF1MAPK14MAPK13MAPK12
SCHEMBL19687669 0.77 RAF1 (0.42) KDM4ERAF1MAPK14MAPK13MAPK12
SCHEMBL30143824 0.73 KDM4A (0.39) KDM4EALDH1A1LMNAHPGDL3MBTL1
SCHEMBL26577880 0.72 KDM4A (0.38) KDM4ELMNAGAAL3MBTL1KDM4A
SCHEMBL13425471 0.72 RAF1 (0.65) RAF1MAPK14MAPK13MAPK12MAPK11
SCHEMBL8255339 0.71 HPGD (0.48) ALDH1A1LMNAMAPTHPGDPPARG
SCHEMBL667203 0.71 RAF1 (0.61) RAF1MAPK14MAPK13MAPK12MAPK11
SCHEMBL101455 0.71 RAF1 (0.42) KDM4EALDH1A1LMNAMAPTRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3774815-A1 THIENOPYRIMIDINONE COMPOUNDS Biotheryx Inc. (US) 2021-02-17 EP disclosed
CN-112313236-A Thienopyrimidinone compounds 拜欧斯瑞克斯公司 2021-02-02 CN disclosed
US-10584133-B2 Thienopyrimidinone compounds BIOTHERYX, INC. (US) 2020-03-10 US disclosed
US-20190322682-A1 THIENOPYRIMIDINONE COMPOUNDS BIOTHERYX, INC. 2019-10-24 US disclosed
WO-2019191451-A1 THIENOPYRIMIDINONE COMPOUNDS BIOTHERYX, INC. (US) 2019-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190322682-A1 THIENOPYRIMIDINONE COMPOUNDS MAVS, BRCA1, HSPE1 KDM4E 2951/4885ALDH1A1 4147/4885LMNA 2974/4885
US-10584133-B2 Thienopyrimidinone compounds MAVS, BRCA1, HSPE1 KDM4E 2951/4885ALDH1A1 4147/4885LMNA 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.